Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure ...
In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
Please provide your email address to receive an email when new articles are posted on . Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic ...
July 16, 2009 (Uppsala, Sweden) — N-terminal pro-brain natriuretic peptide (NT-proBNP) was the only one of a panel of biomarkers that added significant prognostic information to conventional risk ...
ORLANDO -- For patients who were stabilized after acute decompensated heart failure, aggressive management to achieve a 30% reduction in N-terminal pro b-type natriuretic peptide (NT-proBNP) levels ...
In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...
(HealthDay News) — For high-risk patients with heart failure and reduced ejection fraction (HFrEF), an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy does not ...
December 14, 2009 (Basel, Switzerland) — A randomized trial of natriuretic-peptide–guided therapy for heart failure has stopped enrolling patients after an interim analysis showed that the strategy ...
RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback